Your test system for the reliable identification of Helicobacter pylori and its resistances to fluoroquinolones and clarithromycin

According to the National Reference Centre for Helicobacter pylori, approximately 20-30 million people in Germany currently suffer from a Helicobacter infection that requires treatment. In most of these illnesses, initial eradication treatment is successful. Since, however, this initial therapy fails in about 10% of treated patients, it is consequently estimated that there are about half a million people who experience treatment failure!

Because of such failed treatments, the rate of resistance to first-line antibiotics increases. This rate is over 80% for clarithromycin in a patient who has already had several treatments. Consequently alternative antibiotics must be resorted to, for example, from the fluoroquinolone group. But even here, there are already initial resistances in the case of H. pylori. Thus, according to the recommendations of the National Reference Centre for Helicobacter, a biopsy to test resistances should be taken no later than after the first failed treatment, in order to find the best antibiotic combination for the patient.

A very rapid and simple option to detect H. pylori and its resistances is our GenoType® HelicoDR. With this molecular genetic test system, the presence of H. pylori and resistances to fluoroquinolones and clarithromycin are simultaneously detected in a single step. Biopsy material itself as well as culture material extracted from it can be used as the starting material.